Ads
related to: hcv polymerase inhibitors for diabetes mellitus symptoms in women- Find A Local Doctor
Find A Healthcare Professional Near
You To Discuss Treatment Options
- Real Patients With Hep C
See Patient Testimonials For
A Hep C Treatment Option.
- Download Resources
Use These Resources With Your
Healthcare Professional.
- Savings Card
See If You Are Eligible for
a Savings Card.
- Find A Local Doctor
Search results
Results From The WOW.Com Content Network
Protease inhibitors can cause a syndrome of lipodystrophy, hyperlipidemia, diabetes mellitus type 2, and kidney stones. [14] This lipodystrophy is colloquially known as "Crix belly", after indinavir (Crixivan). [15]
HCV genome. Nonstructural protein 5B (NS5B) is a viral protein found in the hepatitis C virus (HCV). [1] It is an RNA-dependent RNA polymerase, having the key function of replicating HCV's viral RNA by using the viral positive RNA strand as a template to catalyze the polymerization of ribonucleoside triphosphates (rNTP) during RNA replication.
Boceprevir (INN, trade name Victrelis) is a protease inhibitor used to treat hepatitis caused by hepatitis C virus (HCV) genotype 1. [2] [3] It binds to the HCV nonstructural protein 3 active site. [4] It was initially developed by Schering-Plough, [5] then by Merck after it acquired Schering in 2009. It was approved by the FDA in May 2011. [6]
Cure rates are 94% to 99% in people infected with hepatitis C virus (HCV) genotype 1. [9] Some evidence also supports use in HCV genotype 3 and 4. [9] It is taken daily by mouth for 8–24 weeks. [8] It is generally well tolerated. [10] Common side effects include muscle pains, headache, nausea, rash, and cough. [8]
HCV is a positive-sense single-stranded RNA virus that has been demonstrated to replicate in the hepatocytes of both humans and chimpanzees. A single HCV polyprotein is translated, and then cleaved by cellular and viral proteases into three structural proteins (core, E1, and E2) and seven nonstructural proteins (p7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B).
Worldwide the prevalence of hepatitis C virus infection in pregnant women and children has been estimated to be 1–8% and 0.05–5% respectively. [153] The vertical transmission rate has been estimated to be 3–5% and there is a high rate of spontaneous clearance (25–50%) in the children.
Ad
related to: hcv polymerase inhibitors for diabetes mellitus symptoms in women